Cargando…

BRCA2 mutations should be screened early and routinely as markers of poor prognosis: evidence from 8,988 patients with prostate cancer

The aim of this study was to focus on clinicopathological characteristics and prognosis in men with prostate cancer (PCa) harboring a breast cancer 2 (BRCA2) gene mutation and to offer convincing evidence to consider BRCA2 mutation as a marker of poor prognosis in the molecular classification of PCa...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Ming, Gao, Xian-Shu, Gu, Xiaobin, Guo, Wei, Li, Xiaoying, Ma, Mingwei, Qin, Shangbin, Qi, Xin, Xie, Mu, Peng, Chuan, Bai, Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522317/
https://www.ncbi.nlm.nih.gov/pubmed/28410213
http://dx.doi.org/10.18632/oncotarget.16712
_version_ 1783252148351401984
author Cui, Ming
Gao, Xian-Shu
Gu, Xiaobin
Guo, Wei
Li, Xiaoying
Ma, Mingwei
Qin, Shangbin
Qi, Xin
Xie, Mu
Peng, Chuan
Bai, Yun
author_facet Cui, Ming
Gao, Xian-Shu
Gu, Xiaobin
Guo, Wei
Li, Xiaoying
Ma, Mingwei
Qin, Shangbin
Qi, Xin
Xie, Mu
Peng, Chuan
Bai, Yun
author_sort Cui, Ming
collection PubMed
description The aim of this study was to focus on clinicopathological characteristics and prognosis in men with prostate cancer (PCa) harboring a breast cancer 2 (BRCA2) gene mutation and to offer convincing evidence to consider BRCA2 mutation as a marker of poor prognosis in the molecular classification of PCa. We searched relevant articles from PubMed, Embase, Web of Science, and the Cochrane Library databases to evaluate the differences in the overall survival (OS) and cancer-specific survival (CSS) between BRCA2 mutation carriers and non-carriers in patients with PCa. We included 525 BRCA2 mutation-carriers and 8,463 non-carriers in total from 10 studies in our meta-analysis. The results showed that carrying a BRCA2 mutation was correlated with a reduced CSS and OS when compared with that of non-carriers, with pooled Hazard Ratios (HRs) of 2.53 (95% confidence interval (CI): 2.10–3.06, P < 0.001) and 2.21 (95% CI: 1.64–2.99, P < 0.001), respectively. The results also demonstrated that BRCA2 mutation-carriers harbored a higher Gleason Score (GS) (> 7), TNM stage (> T3, N1, M1), and risk level than non-carriers. Our meta-analysis showed that a BRCA2 mutation predicted poor survival outcomes in patients with prostate cancer, especially in those undergoing treatments with radiotherapy. Therefore, the use of BRCA2 mutation as a clinical prognostic factor could help stratify the high-risk patients and provide clinical strategies for more effective targeted treatments for patients with prostate cancer.
format Online
Article
Text
id pubmed-5522317
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-55223172017-08-21 BRCA2 mutations should be screened early and routinely as markers of poor prognosis: evidence from 8,988 patients with prostate cancer Cui, Ming Gao, Xian-Shu Gu, Xiaobin Guo, Wei Li, Xiaoying Ma, Mingwei Qin, Shangbin Qi, Xin Xie, Mu Peng, Chuan Bai, Yun Oncotarget Research Paper The aim of this study was to focus on clinicopathological characteristics and prognosis in men with prostate cancer (PCa) harboring a breast cancer 2 (BRCA2) gene mutation and to offer convincing evidence to consider BRCA2 mutation as a marker of poor prognosis in the molecular classification of PCa. We searched relevant articles from PubMed, Embase, Web of Science, and the Cochrane Library databases to evaluate the differences in the overall survival (OS) and cancer-specific survival (CSS) between BRCA2 mutation carriers and non-carriers in patients with PCa. We included 525 BRCA2 mutation-carriers and 8,463 non-carriers in total from 10 studies in our meta-analysis. The results showed that carrying a BRCA2 mutation was correlated with a reduced CSS and OS when compared with that of non-carriers, with pooled Hazard Ratios (HRs) of 2.53 (95% confidence interval (CI): 2.10–3.06, P < 0.001) and 2.21 (95% CI: 1.64–2.99, P < 0.001), respectively. The results also demonstrated that BRCA2 mutation-carriers harbored a higher Gleason Score (GS) (> 7), TNM stage (> T3, N1, M1), and risk level than non-carriers. Our meta-analysis showed that a BRCA2 mutation predicted poor survival outcomes in patients with prostate cancer, especially in those undergoing treatments with radiotherapy. Therefore, the use of BRCA2 mutation as a clinical prognostic factor could help stratify the high-risk patients and provide clinical strategies for more effective targeted treatments for patients with prostate cancer. Impact Journals LLC 2017-03-30 /pmc/articles/PMC5522317/ /pubmed/28410213 http://dx.doi.org/10.18632/oncotarget.16712 Text en Copyright: © 2017 Cui et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (http://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Cui, Ming
Gao, Xian-Shu
Gu, Xiaobin
Guo, Wei
Li, Xiaoying
Ma, Mingwei
Qin, Shangbin
Qi, Xin
Xie, Mu
Peng, Chuan
Bai, Yun
BRCA2 mutations should be screened early and routinely as markers of poor prognosis: evidence from 8,988 patients with prostate cancer
title BRCA2 mutations should be screened early and routinely as markers of poor prognosis: evidence from 8,988 patients with prostate cancer
title_full BRCA2 mutations should be screened early and routinely as markers of poor prognosis: evidence from 8,988 patients with prostate cancer
title_fullStr BRCA2 mutations should be screened early and routinely as markers of poor prognosis: evidence from 8,988 patients with prostate cancer
title_full_unstemmed BRCA2 mutations should be screened early and routinely as markers of poor prognosis: evidence from 8,988 patients with prostate cancer
title_short BRCA2 mutations should be screened early and routinely as markers of poor prognosis: evidence from 8,988 patients with prostate cancer
title_sort brca2 mutations should be screened early and routinely as markers of poor prognosis: evidence from 8,988 patients with prostate cancer
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522317/
https://www.ncbi.nlm.nih.gov/pubmed/28410213
http://dx.doi.org/10.18632/oncotarget.16712
work_keys_str_mv AT cuiming brca2mutationsshouldbescreenedearlyandroutinelyasmarkersofpoorprognosisevidencefrom8988patientswithprostatecancer
AT gaoxianshu brca2mutationsshouldbescreenedearlyandroutinelyasmarkersofpoorprognosisevidencefrom8988patientswithprostatecancer
AT guxiaobin brca2mutationsshouldbescreenedearlyandroutinelyasmarkersofpoorprognosisevidencefrom8988patientswithprostatecancer
AT guowei brca2mutationsshouldbescreenedearlyandroutinelyasmarkersofpoorprognosisevidencefrom8988patientswithprostatecancer
AT lixiaoying brca2mutationsshouldbescreenedearlyandroutinelyasmarkersofpoorprognosisevidencefrom8988patientswithprostatecancer
AT mamingwei brca2mutationsshouldbescreenedearlyandroutinelyasmarkersofpoorprognosisevidencefrom8988patientswithprostatecancer
AT qinshangbin brca2mutationsshouldbescreenedearlyandroutinelyasmarkersofpoorprognosisevidencefrom8988patientswithprostatecancer
AT qixin brca2mutationsshouldbescreenedearlyandroutinelyasmarkersofpoorprognosisevidencefrom8988patientswithprostatecancer
AT xiemu brca2mutationsshouldbescreenedearlyandroutinelyasmarkersofpoorprognosisevidencefrom8988patientswithprostatecancer
AT pengchuan brca2mutationsshouldbescreenedearlyandroutinelyasmarkersofpoorprognosisevidencefrom8988patientswithprostatecancer
AT baiyun brca2mutationsshouldbescreenedearlyandroutinelyasmarkersofpoorprognosisevidencefrom8988patientswithprostatecancer